NF2 Panel
Use
The NF2 Panel evaluates patients with suspected or confirmed Neurofibromatosis Type 2 (NF2), a hereditary tumor predisposition disorder characterized by bilateral vestibular schwannomas, meningiomas, schwannomas, and other central nervous system tumors. The panel includes genes associated with NF2; identification of pathogenic variants informs diagnosis, recurrence risk assessment, family screening, and management decisions.
Special Instructions
Orderable via the GeneDx neurology test menu. Family member testing options are available with no separate report; additional samples must be received within three weeks of the proband sample.
Limitations
Any gene not assessed in its entirety by sequencing and copy‑number assessment is addressed in the Test Methods section (i.e., partial coverage may require reflex testing). Negative results do not rule out mosaicism, deep intronic variants, structural variants not detectable by this assay, or alterations outside assessed regions.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
1 week
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided